VRTX

Vertex Pharmaceuticals
D

VRTX

526.65
USD
-1.08
(-0.20%)
قبل الجلسة·523.86USD-2.79(-0.53%)
حجم التداول
25,195
الربح لكل سهم
19
العائد الربحي
-
P/E
31
حجم السوق
133,485,195,625
الأفكار والتحليلات
هشام منسي
هشام منسي
منذ سنتين
buy
VRTX
VRTXVertex Pharmaceuticals
2024-08-22 06:31
VRTX Chart
المزيد
أصول ذات صلة المقالات
المزيد

العنوان: Vertex Pharmaceuticals

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).